3'-Dephosphocoenzyme A, >=90% (HPLC)

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: 3'-Dephosphocoenzyme A, >=90% (HPLC)
• 英文别名: [[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate
• 化学式: C₂₁H₃₅N₇O₁₃P₂S
• 分子量: 687.6
• InChiKey: KDTSHFARGAKYJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  44
• 可旋转键数：
  16
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  301
• 氢给体数：
  9
• 氢受体数：
  18

文献信息

• PANTOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGIC DISORDERS
  申请人：RETROPHIN, INC.

  公开号：US20130289001A1

  公开（公告）日：2013-10-31

  The present disclosure relates to pantothenate derivatives for the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders.

  本公开涉及泛酸衍生物用于治疗神经系统疾病（如泛酸激酶相关性神经退行性疾病），含有这些化合物的药物组合物，以及它们在神经系统疾病治疗中的应用。
• PANOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：Retrophin, Inc.

  公开号：US20160264607A1

  公开（公告）日：2016-09-15

  Compounds having the following formula (E): Formula E or a pharmaceutically acceptable salt thereof, wherein R, R′, R″, X and n are as defined herein are provided. Methods comprising use of such compounds for the treatment of neurologic disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders are also provided.

  本发明提供具有下列化学式(E)或其药学上可接受的盐的化合物，其中R、R′、R″、X和n如本文所定义。本发明还提供了使用这些化合物治疗神经系统疾病（例如泛酸激酶相关的神经退行性疾病）的方法，以及包含这些化合物的制药组合物和它们在神经系统疾病治疗中的用途。
• Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders
  申请人：Retrophin, Inc.

  公开号：US10364263B2

  公开（公告）日：2019-07-30

  Compounds having the following formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurological disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in the treatment of neurological disorders, also are provided.

  提供了具有下式(I)的化合物及其药学上可接受的盐，其中A、B、D、E和R1如本文所定义。还提供了包括使用此类化合物治疗神经系统疾病（如泛酸激酶相关神经变性）的方法，以及含有此类化合物的药物组合物及其在治疗神经系统疾病中的用途。
• Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk
  申请人：Fred Hutchinson Cancer Research Center

  公开号：US10690651B2

  公开（公告）日：2020-06-23

  The invention disclosed herein generally relates to methods and kits for diagnosing, assessing disease risk, treating, and preventing bacterial vaginosis (BV) and associated conditions. Additional embodiments include methods for developing metabolic profiles associated with increased disease risk, and developing new approaches to treat BV based on interrupting metabolic networks.

  本文公开的发明一般涉及诊断、评估疾病风险、治疗和预防细菌性阴道病（BV）及相关疾病的方法和试剂盒。其他实施方案包括开发与疾病风险增加相关的代谢图谱的方法，以及开发基于干扰代谢网络治疗 BV 的新方法。
• US8673883B2
  申请人：——

  公开号：US8673883B2

  公开（公告）日：2014-03-18